cell

German pharmaceutical firm Boehringer Ingelheim has received approval for olmutinib (BI 1482694 / HM61713) in South Korea, to treat patients suffering from locally advanced or metastatic, epidermal growth factor receptor (EGFR), T790M, mutation-positive, non-small cell lung cancer (NSCLC).

The treatment can work on patients who had previously been treated with an EGFR tyrosine kinase inhibitor (TKI).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hanmi Pharmaceutical will be responsible for distributing the compound in South Korea, under the name olmutinib.

The South Korean approval is based on the successful results of the Phase I/II HM-EMSI-101 (NCT01588145) clinical trial.

Sungkyunkwan University School of Medicine Seoul South Korea Samsung Medical Centre innovative cancer medicine institute (ICMI) director Keunchil Park said: "The approval of olmutinib is a great step forward for lung cancer patients in South Korea.

See Also:

"This is an exciting and much needed new treatment option for the majority of EGFR mutation-positive lung cancer patients whose disease has become resistant to first-line TKI therapy, which can be a devastating development."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This is an exciting and much needed new treatment option for the majority of EGFR mutation-positive lung cancer patients whose disease has become resistant to first-line TKI therapy."

Olmutinib (BI 1482694 / HM61713) is a third-generation, oral, EGFR mutation-specific TKI.

The primary Phase II trial ELUXA 1 (HM-EMSI-202 [NCT02485652]) is under way, thereby enrolling EGFR T790M, mutation-positive lung cancer patients who have become resistant to TKI treatment for the olmutinib treatment.

Last year, Boehringer signed an exclusive license agreement with Hanmi to gain exclusive rights for the product across the globe, except in South Korea and Hong Kong.

ZAI Lab has secured exclusive rights for the product within China, including Hong Kong and Macau.

Image: Micrographs of positive non-small cell lung cancer. Photo: courtesy of Nephron / Wikipedia.